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Abstract
The overall objective of this dissertation was to examine the degree to which
manipulation of the saturated fat content of a high-fat diet influenced obesity-related
outcomes as well as to see if the naturally-occurring flavonoid, quercetin, could attenuate
the resulting obesity and related metabolic and inflammatory side effects. Specifically,
these studies examined 1) the influential role of saturated fat on macrophage function,
inflammation, and other obesity-related comorbidities, including non-alcoholic fatty-liver
disease, and 2) the potential benefits of quercetin supplementation. Overall, results from
these studies suggest that adiposity, macrophage behavior, inflammation, insulin
resistance, and non-alcoholic fatty-liver disease progression can be greatly affected by
dietary SF content. However, it was found that these outcomes are not necessarily
proportional to the percentage of SF in the diet; a diet most closely mimicking the
standard American diet (12% and 40% of overall calories from saturated fat and total fat,
respectively) led to the greatest adiposity, macrophage infiltration into adipose tissue, and
insulin resistance, whereas diets composed of 6% (6%-SF) and 24% (24%-SF) of total
calories from SF, but an equivalent level of overall calories from fat (40%), produced
lower levels of these variables with the 24%-SF diet resulting in the least degree of
insulin resistance and hepatic lipid accumulation. Further, contrary to the findings of
others, the anti-inflammatory flavonoid, quercetin, had no effect at mitigating adipose
tissue inflammation, hepatic steatosis, or improving body composition or fasting blood
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glucose levels in a HFD-induced obesity model. Future studies are needed to better
understand how the interaction between high-fat feeding and quercetin supplementation
influences physiological processes.
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Introduction
The structure of this dissertation is "manuscript style". Thus, each aim of this
dissertation corresponds to an individual journal article representing a chapter.
Consequently, each journal article contains its own abstract, methods, results, and
discussion section as well as references, figure legends, and figures according to the
mandatory manuscript structure requested by the journal to which each article has been,
or will be, submitted.

Review of the Literature
According to the World Health Organization (WHO), it is estimated that 1.5
billion people worldwide are overweight and at least 500 million are obese (1).
Consequently, there has been a rise in obesity-related health problems including, nonalcoholic fatty-liver disease (NAFLD), cardiovascular disease, the metabolic syndrome,
diabetes, degenerative diseases, and cancer (1, 2). Genetic predispositions, physical
inactivity, and consumption of a high-fat diet (HFD) can all lead to the development of
obesity. However, given the global acceptance and availability of energy dense foods,
chronic ingestion of diets high in fat is arguably the leading contributor. As a result,
significant research has been geared towards better understanding the link between highfat-diet-induced obesity (HFDIO) and chronic disease risk as well as investigating
nutrition-based interventions that may be used to combat the obesity epidemic.
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It is now widely accepted that HFDIO can lead to a chronic state of low-grade
inflammation, which is thought to be one of the main contributors to obesity-related
diseases (3-5). This chronic inflammation is largely mediated through quantitative and
functional alterations in white adipose tissue macrophages (ATMs) (6, 7). For example,
it has been reported that approximately 45-60% of adipose tissue (AT) cells express the
macrophage marker EMR1 (F4/80) in obese mice, whereas only 10-15% of cells from
lean mice express this marker (6). In addition, ATMs exhibit a pro-inflammatory,
classical phenotype (M1) in obese mice, while those from lean mice have an
alternatively-activated, anti-inflammatory phenotype (M2) (7). These changes not only
lead to increased inflammation but also to dysregulation of metabolic homeostasis;
infiltration and polarization of macrophages in AT has been linked to lower plasma
adiponectin levels as well as insulin and leptin resistance (8-11).
In addition to promoting a pro-inflammatory environment, obesity also leads to
ectopic lipid accumulation, particularly in the liver. Although the liver is not meant to
store excessive adipose tissue, under conditions in which energy intake exceeds energy
use, the liver is a principal site for fat deposition leading to the development of NAFLD.
NAFLD is the most common cause of chronic liver disease in the world, affecting more
than 30% of the adult population in the United States alone (12, 13). NAFLD has been
linked to cardiovascular morbidity and hepatocellular carcinoma (14).
While the association between HFD-induced obesity and adipose tissue (AT) and
hepatic inflammation has been clearly recognized, there is a fundamental gap in
understanding the relative contribution of different types of fatty acids (FAs) to these
responses. Saturated fatty acids (SFAs) have received significant research attention as a
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result of their ability to influence inflammatory processes. The inflammatory effects of
SFAs are thought to be largely mediated by their capacity to serve as ligands for toll-like
receptor-2 and -4 (TLR-2 and TLR-4); binding of SFAs to TLR-2 and/or TLR-4 on
various cell types, in particular macrophages and adipocytes, results in the induction of
pro-inflammatory gene transcription via activation of nuclear factor kappa-B (NFκB), the
c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK)
signaling cascades (10, 15, 16). Consistent activation of these pathways results in a
chronic state of inflammation and subsequent insulin resistance (IR) (10, 17, 18). In
addition, SFAs, in general, are more obesogenic than other FAs; long-chain saturated
fatty acids (LCSFAs, > C12:0) are not as efficiently oxidized as unsaturated fatty acids
(USFAs), and thus are more likely to be stored as AT (19, 20). Given the preponderance
of evidence that supports a role of saturated fat (SF) on macrophage-mediated
inflammation and metabolic dysfunction in high-fat-diet-induced obesity, it is surprising
that there have been no dose response studies to more clearly evaluate their specific role
in these processes.
Due to the fact that western countries are plagued by diseases resulting from
obesity, it has become the goal of scientists to come up with relatively inexpensive
therapeutic interventions to help mitigate HFD-enhanced chronic inflammation in order
to improve quality of life and decrease obesity-related deaths. Recently, scientists have
utilized nutraceutical interventions to examine the effects that plant-derived metabolites
have on obesity outcomes. There exists promising research that the naturally occurring
flavonoid, quercetin, possesses anti-inflammatory properties and an anti-obesogenic
effect when supplemented along with a HFD (21-27). However, the mechanism(s) by
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which quercetin elicits its positive effects and the influence that quercetin has on
macrophage behavior is still poorly understood. Thus, further investigations are
necessary to better grasp the mechanism(s) by which quercetin produces its therapeutic
benefits.
The overall objective of this dissertation was to examine the degree to which
manipulation of the SF content of a HFD influenced obesity-related outcomes as well as
to see if quercetin supplementation could attenuate the resulting obesity and related
metabolic and inflammatory side effects. Specifically, these studies examined 1) the
influential role of saturated fat on macrophage function, inflammation, and other obesityrelated comorbidities and 2) the potential benefits of quercetin supplementation.

Obesity & Adipose Tissue Dysfunction
Obesity has quickly become a major health concern not only in the United States,
but throughout the world.

Moreover, it seems that the rate of obesity is on the rise. In

1980, as little as thirty years ago, the rate of obesity in the adult population was half
(15%) of what it is now (30%). Even more worrisome, is that WHO projects that by
2015 there will be approximately 2.3 billion and 700 million overweight and obese
individuals, respectively.
The health risks associated with obesity not only affect the individual suffering
from obesity, but they also negatively impact the economy. It is estimated that obesity
costs the economy of the United States more than 120 billion dollars annually (1). The
120 billion dollar stress on the economy is due many factors, including but not limited to:
an increase in health care services that are needed as a direct result of the escalating rate
of obesity and decreased productivity resulting from missed work time and premature
4

death. Additionally, taxpayers are burdened with high health care costs, which impacts
the price of goods and employee raises (2).
Obesity is problematic as the condition is characterized by a chronic state of lowgrade adipocyte inflammation linked to adipose tissue dysfunction. Whether the adipose
tissue dysfunction precedes the low-grade inflammatory state, or vice versa, is debatable.
Nonetheless, adipose tissue dysfunction and the associated low-grade inflammation have
been shown to increase the rate of mortality and are characterized by a circular cascade
of interconnected events including, but not limited to, an increase in adipocyte size and
number, endoplasmic reticulum stress, adipose tissue hypoxia, increased infiltration of
pro-inflammatory macrophages into adipose tissue, an increase in adipocyte, preadipocyte, and macrophage TLR-4 and TLR-2 protein content, an increase in circulating
pro-inflammatory cytokines, insulin resistance, and a decrease in mitochondrial function
(3-9).
Because western countries are plagued by an obesity epidemic, and thus an
increased chronic disease risk, it has become the goal of scientists to uncover the
mechanisms responsible for dysfunctional adipose tissue and the role that certain fatty
acids have in promoting this state.

Dietary Fat and Obesity
It is practically impossible to narrow down the cause of obesity to one single
factor. In reality, the high prevalence of obesity is due to several interacting factors.
These factors include genetics, lifestyle choices (diet and physical activity), as well as the
environment (access to parks, social networks, weather, etc.) (10-12). However, given
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the global acceptance and availability of energy dense foods, chronic ingestion of diets
high in fat is arguably the leading contributor.
Dietary fat consumption is necessary for various physiological functions, and has
been shown to play a major role in preventing chronic conditions such as cardiovascular
disease (13). However, high consumption of dietary fat has been associated with
excessive energy intake, which has been strongly linked to the increasing rate of obesity
within the United States (14). With this being said, research has shown that fat matters,
but total caloric intake is more important (15). From the late 1950’s to the year 2008, it is
estimated that caloric intake, per person, has increased from roughly 1900 kcal to 2,661
kcal – a 761 kcal increase over 58 years (16). This increase in caloric intake is strongly
linked with an increase in the consumption of high-fat foods; according to the USDA, the
average American in the year 2000 consumed 287% more cheese, 41% more meat, and
67% more added fats and oils than the typical American did on an annual basis in the
1950’s.

Standard American Diet and Fat Consumption
In order to educate individuals about nutrient consumption, the United States
Department of Agriculture (USDA) and the Institute of Medicine created daily dietary
guidelines for individuals to follow. These institutes recommend that fat intake be
between 20 – 35% of total caloric intake. With regard to carbohydrate intake,
carbohydrates should make up 45-65% of total caloric intake. Finally, protein intake
should be 10-35% of total caloric intake. Thus, when examining the standard American
diet, one will see that, Americans, in general, consume the three macronutrients
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(carbohydrates, fat, and protein) within the recommended distribution range: the
standard American diet consists of carbohydrate, total fat, and protein consumption to be
50%, 33%, and 15%, respectively, of total caloric intake (17). However, although these
percentages fall within the Dietary Guidelines for Americans (DGA), the types of each
macronutrient, particularly in the case of fats, do not fall within the DGA. For instance, it
is recommended that the majority of fat consumption come from polyunsaturated and
monounsaturated fats and for saturated fat to make up less than 10% of the total calories
consumed. However, in reality, Americans consume 11% of total calories in the form of
saturated fat. In addition, the ratio of monounsaturated to polyunsaturated fat
consumption is roughly 2:1, with monounsaturated fatty acid consumption and
polyunsaturated fat consumption making up 12% and 7%, respectively of total caloric
intake (17).
Recently a significant amount of attention has been given to polyunsaturated fatty
acids and the ratio between Omega-6 polyunsaturated fatty acids to Omega-3
polyunsaturated fatty acids. In general, Omega-6 polyunsaturated fatty acids are
considered to be pro-inflammatory fatty acids, whereas Omega-3 polyunsaturated fatty
acids are considered to be anti-inflammatory fatty acids (18). A high ratio of Omega6/Omega-3 fatty acid consumption has been associated with the promotion of many
chronic diseases, including cancer (18). Ideally, the ratio of Omega-6/Omega-3 fatty acid
consumption should be 1/1 as is seen commonly within the populations of wild animals
and our human ancestors (18-22). However, in the United States, the average
consumption of Omega-6/Omega-3 fatty acids is 15-20/1, a far cry from the ideal ratio
(18).
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Challenges of Dietary Studies
In humans, there are many drawbacks to long-term nutrition studies. Although
such studies can be well designed, high attrition rates and lack of dietary compliance are
two of the biggest problems associated with long-term dietary studies. For instance,
several 6-month studies involving low-carbohydrate diets had attrition rates of 43%,
60%, and 36% (23). Similarly, the attrition rate to a long-term, low-fat diet of roughly
19,000 women was 86% in the Women’s Health Initiative Dietary Modification Trial
(15). Furthermore, it is not plausible to measure repeated multiple physiological markers
(e.g. metabolism, organ function, precise food intake, etc.) over the long term. This is the
reason why you will find few credible long-term dietary studies performed in humans.
Based on this evidence, animal models are better for long-term dietary
interventions when examining the physiological outcomes and mechanisms of various
dietary interventions, as a majority of possible confounding factors can be controlled.
However, even when utilizing animal models, dietary studies still pose a challenge. For
instance, when trying to control for various macro- and micronutrient ratios within an isocaloric diet, the manipulation of one macronutrient, or sub-set of macronutrients, results
in an uncontrollable alteration of another. This is the inherent nature of nutrition studies.
Because of this, with any dietary alteration, it is difficult to pinpoint the macronutrient(s)
responsible for any given outcome. Thus, it is imperative that as much care is taken to
control for as many factors as possible when designing studies centered around nutrient
manipulation.

Non-Alcoholic Fatty-Liver Disease (NAFLD)
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NAFLD is characterized by evidence of hepatic steatosis (as determined by
imaging or histology) with “no causes of secondary hepatic fat accumulation such as
significant alcohol consumption, use of steatogenic medication, or hereditary
disorders”(24). The disease presents itself in 70-80% of diabetic and obese patients and is
the principal cause of hepatological clinical referrals in the United States (24, 25).
NAFLD is a single term describing two pathological conditions. The first condition,
known as hepatic steatosis, is characterized by the accumulation of excess fat in the liver.
Hepatic steatosis precedes the second condition, non-alcoholic steatohepatitis (NASH),
which is typified not only by hepatic steatosis, but also by hepatic inflammation and
hepatocellular damage.
Hepatic steatosis is a product of a long-term imbalance between caloric intake and
energy expenditure. When caloric intake exceeds energy expenditure, excess energy is
stored in the form of triglycerides in adipocytes. Although adipocytes have a significant
capacity to store energy, a prolonged overindulgence in energy intake without a sufficient
matching energy expenditure can result in adipose tissue dysfunction (26). Adipose
tissue dysfunction is characterized by many factors including, an increase in adipocyte
size and number, adipocyte secretion of pro-inflammatory cytokines, as well as the
promotion of a pro-inflammatory environment and ectopic fat deposition, including the
liver (26, 27). As lipids continue to accumulate in the liver, the liver eventually becomes
insulin resistant, inflamed, and fibrotic (NASH), leading to an increased risk of mortality
(24).
Mounting evidence suggests that HFDs promote NAFLD (28, 29). Further, it
seems the type of fat consumed in the diet can greatly affect the development of NAFLD
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(25); both in vitro and in vivo models provide evidence that diets higher in saturated fat
induce endoplasmic reticulum (ER) stress, modulate mitochondrial metabolism, promote
an inflammatory environment, and invoke liver damage (25, 30, 31). However, there
have been no controlled studies, which have examined the effects of HFDs different in
the percentage of saturated fat on NAFLD.
Although NAFLD is a relatively common disease within the United States and
throughout the world, there are limited therapeutic interventions for this condition.
Weight loss through lifestyle interventions has proven successful at perturbing NAFLD
(24, 32), however, it is difficult for individuals to successfully maintain long-term weight
loss. In addition to exercise and diet modifications, such drugs as thiazolidinediones and
statins have been shown to attenuate hepatic steatosis and steatohepatitis (32), however,
the long-term safety and effectiveness of these drugs is unknown.

Saturated Fat
SFAs are FAs that have no double bonds between any of the carbon atoms in the
FA chain. Thus, each carbon atom is “saturated” with hydrogen atoms. Various foods
found throughout nature contain abundant amounts of SF. These foods include oils, such
as coconut, cottonseed, and palm kernel oil, as well as foods rich in animal fats (e.g.
cheese, fatty meats, cream, etc.). The majority of SF consumed by the typical American
stems from animal foods.
Increased SFA consumption was first implicated as a risk factor for
cardiovascular disease (CVD) based upon studies conducted in the 1960s-70s as this
augmented consumption was shown to increase low-density lipoprotein (LDL)
cholesterol more than any other nutrient except for trans fatty acids (33). For this reason,
10

both the WHO and the U.S. Dietary guidelines and the American Heart Association
recommend that consumption of SF should be limited to 10% and 7% of total caloric
intake, respectively (34).
It was not until recently that it was discovered that SFAs are capable of serving as
ligands for TLR-4 and TLR-2, leading to the induction of pro-inflammatory gene
transcription via nuclear factor kappa-B (NF-κB) activation (35, 36). TLR-4 and TLR-2
are part of a family of trans-membrane receptors that recognize conserved molecular
patterns found on exogenous and endogenous pathogens and are ubiquitously expressed
on cells found throughout the body (37). TLRs serve as an integral part of the innate
immune system; once coupled to their specific ligand, TLRs help to activate immune
system responses in order to protect the host from infection.
Consistent activation of the TLR-NF-κB pathway can lead to insulin resistance
and a chronic state of inflammation, which has been shown to stimulate metabolic
diseases and cancer development and contribute to adipose tissue dysfunction (3, 9, 3840). Additionally, although the rate of saturated fat oxidation increases with decreasing
carbon number, the long-chain saturated fatty acids (LCSFAs, > C12:0), are not as
efficiently oxidized as unsaturated fatty acids, and thus are more likely to be stored as
adipose tissue, elevating the risk of excess fat-mass gain and ectopic fat deposition (41,
42). It is common knowledge that white adipose tissue (WAT) is the main storage site
for fatty acids in the form of triglycerides. The fatty-acid composition of WAT is
primarily dependent on the fatty acid composition of the diet (43). Thus, individuals who
consume a diet that is higher in saturated fat, such as the typical American diet, will have
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WAT that consists of a larger percentage of saturated fat than an individual consuming a
diet that is significantly lower in saturated fat.
Acute or chronic inflammation, obesity, IR and high-fat feeding are known to
increase lipolysis and increase plasma free-fatty acid (FFA) levels (7, 44). Consequently,
lipolysis of WAT comprised of a greater proportion of saturated fatty acids will lead to
elevated circulating saturated FFAs, which may serve as ligands for TLR-4 and TLR-2,
ultimately leading to pro-inflammatory gene expression. The pro-inflammatory proteins
produced from these genes can then feedback into the circular inflammatory cascade,
compounding adipose tissue dysfunction, augmenting the chronic inflammatory state, and
increasing the risk of cancer development. Furthermore, high-fat feeding, leading to
excess adipose tissue accumulation, has been shown to up-regulate TLR-4 expression on
adipocytes, pre-adipocytes, and macrophages, thus enhancing the sensitivity of these cells
for TLR-4 specific ligands, notably saturated fatty acids (7, 45).

Quercetin
Plants and plant-derived foods, such as fruits and vegetables, are comprised of
thousands of non-caloric, naturally-occurring chemical compounds known as
phytochemicals. It is believed that the health benefits derived from fruits and vegetables
largely stem from these compounds, as upon consumption, phytochemicals are known to
possess numerous functional qualities beneficial to the body (46). One of the most
abundant phytochemicals found in plant-derived foods is quercetin. In fact, human
consumption of quercetin in the diet is estimated to be 5-40 mg/day and as high as 500
mg/day in those individuals consuming a plant-based diet (46).
12

Quercetin, along with other phytochemicals, has been linked to the prevention of
various diseases including cardiovascular disease (CVD), cancer, and NAFLD.
Epidemiological research has provided evidence that an inverse relationship exists
between phytochemical consumption and coronary heart disease and stroke (46). In
addition, various animal and in vitro investigations have shown that quercetin has the
capacity to serve as a mediator of cancer, CVD, and NAFLD development (46-54).
Quercetin’s ability to serve as an anti-inflammatory, antioxidant, anti-proliferative, proapoptotic, and anti-angiogenic agent, as well as a regulator of metabolism, is believed to
the basis for the positive effects elicited by the nutraceutical (46, 55).
Specifically, it has been quercetin’s capability to influence metabolic processes
and its anti-inflammatory property, which have gained the attention of researchers
examining obesity-related diseases. For instance, a study performed by Jung et. al. found
that, in mice, a 32% HFD supplemented with .025% quercetin for 9 weeks reduced body
weight, liver weight, and white adipose tissue weight compared to mice consuming a
HFD without quercetin (53). In addition, it was found that quercetin altered the mRNA
expression of genes regulating lipid metabolism. Along a similar note, in mice, Koboriet.
al., also found that a HFD supplemented with .05% quercetin for 20 weeks hindered the
development of hepatic steatosis, reduced visceral adipose tissue accumulation, oxidative
stress, and improved glucose metabolism (52). These changes were linked to the
normalization of mRNA expression of genes associated with regulating hepatic steatosis.
These studies provide evidence that quercetin does possess anti-obesogenic properties,
and these properties may be regulated by genes involved in lipid metabolism. However,
investigations have also shown that quercetin supplementation can elicit mitochondrial
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biogenesis both in the brain and in skeletal muscle (56, 57). Given that the mitochondria
is the primary organelle involved in aerobic respiration and energy metabolism, it is
plausible that quercetin’s anti-obesogenic property is related to the flavanoid’s influence
on mitochondria.
Regarding quercetin’s anti-inflammatory property, Panchalet. al. found that a
HFD supplemented with quercetin (.8 g/kg) reduced abdominal obesity and symptoms
associated with the metabolic syndrome in rats (58). These findings were associated with
a decrease in the concentration of NF-κB, leading the researchers to believe that a
reduction in inflammation was partly responsible for quercetin’s anti-obesogenic effects.
Ying et. al. also found that 14 days of daily oral administration of quercetin (30-60
mg/kg) given to gerbils on a HFD significantly reduced circulating levels of TNF-α and
IL-6, two pro-inflammatory cytokines, while simultaneously positively influencing the
lipid profile and decreasing hepatic lipid accumulation (54). These are just three
examples of several studies to show that quercetin can mitigate HFD-induced
inflammation (59-62). Although it is evident that quercetin does possess an antiinflammatory property, the mechanism through which quercetin elicits its antiinflammatory effects are still poorly understood. However, there is evidence indicating
that quercetin tempers inflammation via modulation of the NF-κB and JNK pathways
(63-66). Nonetheless, no studies have examined the influence of a HFD supplemented
with quercetin on AT macrophage behavior.
Although strong evidence exists suggesting that quercetin possesses both antiobesogenic and anti-inflammatory properties and may ameliorate the metabolic
syndrome, at least one study performed by Stewart et. al., has shown that quercetin
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supplementation may not improve insulin sensitivity (67). In Stewart’s study, over a
period of 8 weeks, mice consumed HFDs supplemented with or without 1.2% quercetin.
Insulin signaling in various tissues was examined using euglycaemic-hyperinsulinaemic
clamps at 3 and 8 weeks. The researchers found that quercetin did not successfully
mitigate IR. Unfortunately, inflammatory markers were not measured in this particular
study, thus the authors were unable examine the link between quercetin supplementation,
IR, and inflammation.

Limitations of Previous Studies
Although there is an overabundance of studies that have examined the influence
of high-fat feeding on various physiological markers, they are many limitations to these
investigations. Such limitations include: 1) the utilization of a single high-fat diet, 2) the
utilization of a diet with greater than 50% of total calories from fat and or greater than
30% of total calories from saturated fat, 3) lack of control for various nutrients (e.g. ratio
of MUFA:PUFA; omega-6:omega-3 FAs; protein:carbohydrate:fat, etc.), 4) and
utilization of a single ingredient as the sole source of dietary fat (e.g. corn oil, beef
tallow, milk fat, etc.).
The reader will notice that the majority of previous studies have been limited by
lack of control for various factors related to diet. This is the exact reason why the diets
that will be utilized in this dissertation have been carefully selected and manipulated to
not only mimic the composition of the Standard American Diet, but also to control for as
many potential outcome-influencing factors as possible.
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Chapter II

Influence of Dietary Saturated Fat Content on Adiposity, Macrophage Behavior,
Inflammation, and Metabolism: Composition Matters1

1

Enos, R. T., J. M. Davis, K. T. Velazquez, J. L. McClellan, S. D. Day, K. A. Carnevale,
and E. A. Murphy. 2013. J Lipid Res 54: 152-163.
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ABSTRACT
We examined the effects of three high-fat diets differing in the percentage of total
calories from saturated fat (SF) (6%, 12%, and 24%), but identical in total fat (40%), on
body composition, macrophage behavior, inflammation, and metabolic dysfunction in
mice.
Diets were administered for 16 weeks. Body composition and metabolism (glucose,
insulin, triglycerides, LDL-C, HDL-C, total cholesterol) were examined monthly.
Adipose tissue (AT) expression of marker genes for M1 and M2 macrophages and
inflammatory mediators (TLR-2, TLR-4, MCP-1, TNF-α, IL-6, IL-10, SOCS1, IFN-γ)
was measured along with activation of NFκB, JNK and p38-MAPK. AT macrophage
infiltration was examined using immunohistochemistry. Circulating MCP-1, IL-6,
adiponectin, and leptin were also measured. SF content, independent of total fat, can
profoundly affect adiposity, macrophage behavior, inflammation, and metabolic
dysfunction. In general, the 12%-SF diet, most closely mimicking the standard American
diet, led to the greatest adiposity, macrophage infiltration, and insulin resistance (IR),
whereas the 6%-SF and 24%-SF diets produced lower levels of these variables with the
24%-SF diet resulting in the least degree of IR and the highest TC/HDL-C ratio.
Macrophage behavior, inflammation and IR following HFDs are heavily influenced by
dietary SF content, however, these responses are not necessarily proportional to the SF%.

Keywords: Saturated Fat, High-Fat Diet, Macrophages, Inflammation, Obesity
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INTRODUCTION

According to the World Health Organization, It is estimated that 1.5 billion
people worldwide are overweight and at least 500 million are obese (1). Consequently,
there has been a rise in obesity-related health problems including, cardiovascular disease,
the metabolic syndrome, diabetes, degenerative diseases, and cancer (1, 2). Genetic
predispositions, physical inactivity, and consumption of a high-fat diet (HFD) can all lead
to the development of obesity. However, given the global acceptance and availability of
energy dense foods, chronic ingestion of diets high in fat is arguably the leading
contributor. As a result, there has been a major emphasis on understanding the link
between high-fat-diet-induced obesity and chronic disease risk. In this context, lowgrade chronic inflammation has emerged as a key pathogenic link (68-70).
It is now widely accepted that high-fat-diet-induced obesity can lead to a chronic
state of low-grade inflammation. This is largely mediated through quantitative and
functional alterations in white adipose tissue macrophages (ATMs) (71, 72). For
example, it has been reported that approximately 45-60% of adipose tissue (AT) cells
express the macrophage marker EMR1 (F4/80) in obese mice, whereas only 10-15% of
cells from lean mice express this marker (71). In addition, ATMs exhibit a proinflammatory, classical phenotype (M1) in obese mice, while those from lean mice have
an alternatively-activated, anti-inflammatory phenotype (M2) (72). These changes not
only lead to increased inflammation but also to dysregulation of metabolic homeostasis;
infiltration and polarization of macrophages in AT has been linked to lower plasma
adiponectin levels as well as insulin and leptin resistance (4, 6, 7, 73). While the
association between high-fat-diet-induced obesity and macrophage-mediated
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inflammation has been clearly recognized, there is a fundamental gap in understanding
the relative contribution of different types of fatty acids (FAs) to these responses.
Saturated fatty acids (SFAs) have received the most attention for their ability to
influence pro-inflammatory processes in high-fat-diet-induced obesity. These effects are
thought to be largely mediated by their capacity to serve as ligands for toll-like receptor 2
and 4 (TLR-2 and TLR-4); binding of SFAs to TLR-2 and/or TLR-4 on various cell
types, in particular macrophages and adipocytes, results in the induction of proinflammatory gene transcription via activation of nuclear factor kappa-B (NFκB), the cJun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (p38 MAPK)
signaling cascades (7, 35, 74). Consistent activation of these pathways results in a
chronic state of inflammation and subsequent insulin resistance (IR) (7, 39, 40). In
addition, SFAs, in general, are more obesogenic than other FAs; long-chain saturated
fatty acids (LCSFAs, > C12:0) are not as efficiently oxidized as unsaturated fatty acids
(USFAs), and thus are more likely to be stored as AT (41, 42). Given the preponderance
of evidence that supports a role of saturated fat (SF) on macrophage-mediated
inflammation and metabolic dysfunction in high-fat-diet-induced obesity, it is surprising
that there have been no dose response studies to more clearly evaluate their specific role
in these processes.
The purpose of this study was to examine the effects of three HFDs differing in
the percentage of total calories from SF (6%, 12%, and 24% of total caloric intake), but
identical in total fat (40%), on body composition, macrophage behavior, inflammation,
and metabolic dysfunction in mice. We hypothesized that high dietary fat intake would

28

increase adiposity, macrophage infiltration, inflammation, IR, and impair the lipid
profile, and that these effects would be augmented as the percentage of SF increased.

METHODS
Animals
Male C57BL/6 mice were bred and cared for in the animal facility at the
University of South Carolina. They were housed, four-five per cage, maintained on a
12:12-h light-dark cycle in a low stress environment (22°C, 50% humidity, low noise)
and given food and water ad libitum. Principles of laboratory animal care were followed,
and the Institutional Animal Care and Usage Committee of the University of South
Carolina approved all experiments.

Diets
At four weeks of age, mice were randomly assigned to 1 of 5 treatment diets
(n=8-9/group): two control diets (AIN-76A, AIN-76A Mod) and three HFDs (6%-SF,
12%-SF, and 24%-SF) (BioServ, Frenchtown, NJ) (Table 2.1). The percentage of
calories provided by each of the three macronutrients, the ratio of
polyunsaturated:monounsaturated FAs (PUFA:MUFA), and the ratio of omega-6:omega3 FAs were identical for the HFDs and were designed to be similar to the standard
American diet (17, 18). The second control diet (AIN-76A Mod) was used in order to
match the PUFA:MUFA and omega-6:omega-3 ratios of the HFDs.
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Body weights, food intake, and body composition
Body weight and food intake were monitored weekly. Body composition was
assessed every four weeks (weeks 4, 8, 12, 16, and 20). For this procedure, mice were
placed under brief anesthesia (isoflurane inhalation) and were assessed for lean mass, fat
mass, and body fat percentage via dual-energy x-ray absorptiometry (DEXA) (Lunar
PIXImus, Madison, WI).

Metabolism
Plasma was assessed for fasting concentrations of glucose, insulin, total
cholesterol (TC), HDL-C, and triglycerides at weeks 8, 12, 16 and 20 and for LDL-C at
weeks 16 and 20. Blood samples were collected from the tip of the tail after a five-hour
fast. Blood glucose concentrations were determined in whole blood using a glucometer
(Bayer Contour, Michawaka, IN). Collected blood was centrifuged and plasma was
aliquoted and stored at -80°C until analysis. Insulin concentrations were determined
using an ELISA kit (Mercodia, Uppsala, Sweden) and colorimetric kits were used for
plasma triglycerides (Pointe Scientific, Canton, Michigan), TC, HDL-C, and LDL-C
(Genzyme, Kent, United Kingdom). Insulin resistance was estimated by HOMA index as
follows: insulin resistance index = fasting insulin (μU/ml) x fasting glucose
(mmol/l)/22.5 (75).

Tissue collection
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At 20 weeks of age, mice were sacrificed for tissue collection. Epididymal,
mesentery, and retroperitoneal fat pads were removed, weighed, and immediately snapfrozen in liquid nitrogen and stored at -80°C or fixed in 10% formalin until analysis.
Blood was collected from the inferior vena cava using heparinized syringes, and
centrifuged at 4,000 rpm for 10 min at 4°C. Plasma was aliquoted and stored at −80°C.

Adipocyte size and F4/80 immunohistochemistry
At sacrifice, a portion of epididymal AT was excised from each mouse, fixed
overnight in 10% formalin, dehydrated with alcohol and embedded in wax. Paraffin
sections were stained with hematoxylin and eosin (H&E). The surface area of 100
adipocytes was determined (manual trace) and then averaged to represent mean adipocyte
size for each mouse using Infinity Analyze software (Lumenera, Ottawa, ON). F4/80
staining was performed in epididymal AT using rat monoclonal antibody (Serotec,
Raleigh, NC). Color detection was visualized with a Vectastain avidin-biotinylated
enzyme complex detection kit (R&D Systems, Minneapolis, MN), and 3,3´diaminobenzidine followed by counterstaining with hematoxylin.

Western blots
Epididymal AT was homogenized in radioimmunoprecipitation buffer (Sigma, St.
Louis, MO), which included a protease inhibitor cocktail (Sigma, St. Louis, MO), and 1%
glycerophosphate (100x), 0.5% sodium orthovanadate (1 mM), and 1% sodium fluoride
(5 mM). The protein concentration was determined by the Bradford method (76).
Western blots were performed as previously described using primary antibodies for
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phosphorylated (Ser536) and total NFkB p65, phorphorylated (Thr183/Tyr185) and total
JNK (Cell Signaling, Danvers, MA), and phosphorylated (Tyr182) and total p-38
MAPK (Santa Cruz Biotechnology Inc., Santa Cruz, CA) (77). As there were no
differences in the activation of any of the measured proteins between the two control
diets (AIN-76A and AIN-76A Mod), these samples were combined to represent the
“control” diets for these analyses.

Gene expression
Epididymal AT was homogenized under liquid nitrogen using a polytron and total
RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) and RNeasy minispin columns (Qiagen, Valencia, CA). Quantification of epididymal AT gene expression
for F4/80, CD11c, CD206, MCP-1, IL-6, SOCS1, TLR-4, TLR-2, TNF-α, IFN-γ and IL10 (Applied Biosystems, Foster City, CA) were performed as previously described (78).

Concentration of circulating markers of obesity and inflammation
Plasma concentrations of leptin, adiponectin, IL-6, and MCP-1 were determined
using commercially available ELISA kits (R&D Systems, Minneapolis, MN).

Statistical analysis
All data were analyzed using commercial software (SigmaStat, SPSS, Chicago,
IL). Body weight, body composition outcomes, metabolic outcomes, the TC:HDL-C
ratio, and the HOMA index were analyzed using a repeated measures two-way ANOVA.
All other data were analyzed using a one-way ANOVA. Student-Newman-Keuls test
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was used for all post-hoc analyses. Statistical significance was set with an alpha value of
P≤0.05. Data are presented as mean (±SEM).

RESULTS
12%-SF consumption leads to heavier body weights, larger adipocyte size, and
greater fat mass than any other diet
Body weights, fat pad weights, and average adipocyte size are presented in Figure
2.1. The mice consuming the 12%-SF diet had significantly elevated body weights
compared to control-diet-fed mice starting at 11 weeks of age (P<.05), but this effect
began later for 6%-SF and 24%-SF-fed mice (weeks 12 and 13 compared to AIN-76A
and AIN-76A Mod, respectively) (P<.05). Further, the 12%-SF-fed mice had greater
body weights than both 6%-SF-fed mice (starting at week 15) and 24%-SF-fed mice
(starting at week 17) (P<.05).
For all fat-pad depots, the HFD-fed mice had enhanced fat mass compared to
control-diet-fed mice (P<.05). Although there was no difference among HFDs with
respect to total visceral AT, the 12%-SF-fed mice had a greater mesentery fat weight than
both the 6%-SF and 24%-SF-fed mice (P<.05).
As expected, HFD consumption increased adipocyte size compared to control-diet
consumption (P<.05). When comparing across HFD-fed mice, the 12%-SF-fed mice had
the largest adipocyte size followed by 6%-SF and 24%-SF-fed mice, respectively
(P<.05).
Body composition analysis revealed a significant difference among groups
(P<.05) (Table 2.2). Specifically, the 12%-SF-fed mice had a greater body fat percentage
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compared to control-diet-fed mice (starting at 12 weeks) and 24%-SF-fed mice (16
weeks) (P<.05). However, the 24%-SF and 6%-SF-fed mice did not differ from controldiet-fed mice until week 16. There were no significant differences in body fat
percentages across the HFD-fed mice at 20 weeks-(P<.05). On the other hand, at week
20, the 12%-SF-fed mice did have a greater fat mass than the 24%-SF and 6%-SF-fed
mice (P<.05). In general, lean mass increased over time for all groups, and by week 16,
the HFD-fed mice exhibited greater lean mass compared to control-diet-fed mice (P<.05).
It was not possible to calculate individual food intake as mice were housed 45/cage. However, in general, we did not observe any differences, among the HFD-fed
mice, in weekly food intake (food consumed by mice in each cage/number of mice in
cage) over the course of the study.

ATM infiltration is greatest in 12%-SF-fed mice
Expression of F4/80, CD11c (M1) and CD206 (M2) was greater with the
consumption of the 12%-SF diet compared to all other diets (P<.05), with the exception
of no difference in CD206 between the 12%-SF and 6%-SF-fed mice (Figures 2.2A-C).
Interestingly, we did not detect a difference in TLR-4 expression across the groups (data
not shown), however, TLR-2 expression (Figure 2.2D) was increased with the
consumption of the 12%-SF diet compared to all other diets, except the 6%-SF diet
(P<.05). We next confirmed inflammation and macrophage infiltration in AT via H&E
and immunohistochemistry staining of F4/80, respectively. The 12%-SF-fed mice
showed increased inflammation (Figure 2.2E) and accumulation of macrophages in the
AT (Figure 2.2F) compared to control-diet-fed mice. Although the 6%-SF and 24%-SF-
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fed mice also exhibited increased inflammation and macrophage infiltration, these effects
were not as pronounced as in 12%-SF.

Adipose tissue inflammation is influenced by the content of dietary fat
There was no difference in the activation of p-38 MAPK among any of the diets
(Figure 2.33A). Alternatively, the activation of JNK, was significantly increased in all
HFDs (P<.05) (Figure 2.33B). However, only 12%-SF exhibited a higher degree of
NFκB p65 activation (P<.05) (Figure 2.3C).
Consumption of all HFDs led to increased expression of MCP-1 in epididymal
AT compared to control diets (P<.05) (Figure 2.4A). TNF-α, was increased in 6%-SF
and 12%-SF-fed mice only (P<.05) (Figure 2.4B), but there were no differences in IL-6
(Figure 2.4C) or IFN-γ (Figure 2.4D) expression among any of the groups. Interestingly,
SOCS1 expression was significantly decreased in the 24%-SF-fed mice only (P<.05)
(Figure 2.4E). Regarding the anti-inflammatory cytokine, IL-10, we found increased
expression in the 12%-SF-fed mice only (P<.05) (Figure 2.4F).

Circulating leptin is greatest with the 12%-SF diet
For leptin, not only did all HFDs exhibit significantly elevated plasma
concentrations compared to control diets, but there were also differences among HFDs;
the 12%-SF-fed mice had increased leptin levels compared to 6%-SF and 24%-SF-fed
mice (P<.05) (Figure 2.5D). However, there were no significant differences across the
groups for circulating levels of IL-6, MCP-1, or adiponectin (Figures 2.5A-C).
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The 12%-SF diet leads to the greatest IR, followed by 6%-SF and 24%-SF diets,
respectively.
Beginning at week 16, all three HFDs produced higher fasting blood glucose
concentrations compared to control diets (P<.05), but by 20 weeks, only the 6%-SF and
12%-SF-fed mice had elevated fasting blood glucose concentrations (P<.05) (Table 2.3).
And in fact, the 12%-SF-fed mice exhibited a higher fasting blood glucose in comparison
with the 24%-SF-fed mice at this time (P<.05).
All HFD-fed mice had elevated insulin levels compared to control-diet-fed mice
at 16 and 20 weeks (P<.05). However, at 16 weeks the 12%-SF-fed mice had increased
levels compared to the 6%-SF and 24%-SF-fed mice (P<.05), and at 20 weeks, both the
6%-SF and 12%-SF-fed mice had elevated levels versus the 24%-SF-fed mice (P<.05).
Similar to insulin, HFD-fed mice had a greater HOMA index than control-diet-fed
mice at 16 weeks (P<.05). However, at week 20, not only were the HFD groups different
from the control-diet groups, but they were different from each other; the 12%-SF groups
had the greatest HOMA score, followed by 6%-SF and 24%-SF groups (P<.05).

Changes in lipid profile are influenced by SF content
The 12%-SF-fed mice had elevated TC compared to control-diet-fed mice at week
8 (P<.05). By week 12 and 16, the 6%-SF and 12%-SF-fed mice had increased levels
compared to the AIN-76A-fed mice (week 12) and AIN-76A-Mod-fed mice (week 16),
respectively (P<.05). All HFD-fed mice had a greater plasma concentration of TC versus
the control-diet-fed mice at 20 weeks (P<.05), but within the HFD groups, the 12%-SF
group had significantly greater TC versus the 24%-SF group (P<.05).
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In general, the plasma HDL-C concentration tended to be highest with the
consumption of the 24%-SF diet. Statistically, mice consuming the 24%-SF diet
exhibited significantly elevated HDL-C levels compared to the control-fed mice (week
8), 6%-SF-fed mice (week 16), and 12%-SF-mice (week 8, 16 and 20) (P≤.05).
Interestingly, however, there were no significant changes in HDL-C concentrations for
any of the groups over time. Both the 6%-SF and 12%-SF-fed mice had a greater
TC/HDL-C ratio than all other mice at week 20 (P<.05). LDL-C, measured at weeks 16
and 20 only, was elevated in all HFD-fed mice compared to control-diet-fed mice
(P<.05). Differences in triglycerides across the groups were detected at 20 weeks only;
the 24%-SF-fed mice and AIN-76A-Mod-fed mice had the highest and lowest levels of
triglycerides, respectively (P<.05)

DISCUSSION
HFDs are strongly linked with the accumulation of excess body fat, chronic
inflammation, and metabolic perturbations, ultimately leading to poorer health outcomes.
It is well known that ATMs play a central role in this relationship (79). However, the
extent to which the FA composition of a HFD influences macrophage behavior and
inflammation is still poorly understood; most of the available supporting literature is
limited by the lack of control for various nutrients (e.g. ratio of MUFA:PUFA; omega6:omega-3 FAs; protein:carbohydrate:fat, etc.), the utilization of a single ingredient as the
sole source of dietary fat (e.g. corn oil, beef tallow, milk fat, etc.) and the absence of dose
response studies. We examined the effect of three HFDs differing in the percentage of
total calories from SF (6%, 12%, and 24%), but identical in total fat (40%), on adiposity
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(absolute fat mass), macrophage phenotype, inflammation, and metabolism utilizing
controlled diets consisting of various lipid-rich ingredients. Our findings indicate that
manipulating the SF content, without changing the percentage of total calories from fat,
has a profound effect on these outcomes. The 12%-SF diet, most closely mimicking the
standard American diet, led to the greatest adiposity (absolute fat mass), macrophage
infiltration, and IR. Although the 24%-SF diet increased adiposity and produced IR, it
did not significantly increase macrophage infiltration, it led to a lesser degree of AT
inflammation, and it did not raise the TC/HDL-C ratio.
Given that SFAs, in general, are less efficiently oxidized than USFAs, we
hypothesized that adiposity would be greatest following consumption of the 24%-SF diet
(41, 42). Interestingly, despite the fact that HFD-fed mice consumed similar kcals, the
12%-SF diet led to the greatest accumulation of fat and the largest adipocyte size
followed by the 6% and 24%-SF groups, respectively. We also confirmed that plasma
leptin was proportional to the degree of fat-mass accumulation as previously reported (6).
The FA composition of AT is primarily dependent on the FA composition of the
diet (80). Therefore, lipolysis of white adipose tissue (WAT) that is comprised of a
greater proportion of SFAs should lead to higher levels of circulating saturated free-fatty
acids and subsequent activation of macrophages through binding to TLRs (7, 74). Given
this, we expected that a diet higher in SF content would lead to greater macrophage
infiltration and more pronounced inflammation. In agreement with previously reported
literature (29), all HFDs increased expression of F4/80 as well as markers for M1 and M2
macrophages; interestingly, however, these reached statistical significance only in the
12%-SF group. The activation of macrophages in AT is thought to be mediated by TLRs;
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both TLR-2 and TLR-4 have been implicated in HFD-induced macrophage activation and
inflammation given their ability to bind saturated free-fatty acids (74, 81, 82). Consistent
with the macrophage data, we show a statistically significant increase in TLR-2
expression only in the 12%-SF-fed mice, but surprisingly there was no significant upregulation of TLR-4 in any of the HFD groups. To our knowledge, there have been no
reports of an up-regulation of WAT TLR-2 expression without significant changes in
WAT TLR-4 expression following HFD feedings. These results warrant further
investigation into the role that individual TLRs play in HFD-induced inflammation, and
conversely, the effect that varying the composition of HFDs has on TLR activation.
Because macrophages are thought to mediate their inflammatory processes
through activation of various transcription factors (7, 35, 74), we next examined
phosphorylated NFκB, JNK, and p38 MAPK and found that all three HFDs increased
activation of JNK, whereas only the 12%-SF diet significantly increased NFκB
activation. All HFD-fed-mice exhibited an increase in mRNA expression of MCP-1 in
AT, and the 6%-SF and 12%-SF-fed mice, but not the 24%-SF-fed mice, exhibited an
increase in TNF-α mRNA expression. Surprisingly, IFN-γ, that has been shown to be upregulated in WAT and play a key role in macrophage activation in HFD-induced obesity
(83), was not statistically different across diets. This may be due to the specific
measurement time-point, the composition of these novel diets, or most likely, an increase
in factors that can regulate expression of IFN-γ. Additionally, we found no changes in
AT IL-6 mRNA expression across groups. Although previous studies have shown AT
IL-6 mRNA expression to be up-regulated as a result of high-fat feeding (84, 85), others
have shown that this is not always the case (86). We also measured IL-10, an anti-
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inflammatory cytokine, and found it to be up-regulated in the 12%-SF mice only, which
is most likely a compensatory response to the increased inflammation (87). Interestingly,
SOCS1 a negative regulator of inflammation (88), appeared to be down-regulated in all
the HFDs but this reached significance in the 24%-SF group only. Circulating markers of
inflammation (MCP-1, IL-6) were measured to determine whether they mirrored the
observed changes in WAT as has previously been reported (85, 89). We found no
significant increases in plasma MCP-1 or IL-6 for any of the HFDs. The most likely
explanation for the discrepancies between our findings and those of others is the
differences in the composition of the diets used.
Emerging evidence suggests that pro-inflammatory M1 macrophages may play a
role in inducing IR, whereas alternatively activated M2 macrophages may help to
maintain insulin sensitivity (84). Our data somewhat supports this hypothesis as the
degree of M1 macrophage mRNA expression corresponds well with the level of IR; the
12%-SF diet resulted in the most severe IR, followed by the 6%-SF and 24%-SF diets,
respectively. However, given that M1 macrophage quantification in this study was
limited to mRNA expression of CD11c this association should be interpreted with
caution. Adiponectin, well characterized as an anti-inflammatory adipocytokine, known
to promote insulin sensitivity, has been shown to be inversely correlated with body fat
accumulation (6). Interestingly, there were no changes in the concentration of plasma
adiponectin across groups. It is likely that changes in adiponectin would have been
observed if it had been measured in the WAT (90), however, our analysis was limited to
plasma levels. Concerning lipid metabolism, all three HFDs increased TC and LDL-C
levels. Of interest was the finding that although the 24%-SF diet increased LDL-C and
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elevated plasma triglycerides, it also resulted in a higher HDL-C level, producing a more
favorable TC/HDL-C similar to that of control diets.
A possible explanation for the discrepancies in adiposity (absolute fat mass), IR,
inflammation, and the TC/HDL-C ratio between the 12%-SF-fed mice and the 24%-SFfed may be the difference in the content of medium-chain fatty acids (C8:0-C12:0)
(MCFAs) (3.6%, and 11.8% of total caloric intake for the 12%-SF, and 24%-SF diets,
respectively). These variations exist as it was not possible for the composition of the SF
in each of the HFDs to be consistent while utilizing various lipid-rich ingredients and
simultaneously controlling for the omega-6:omega-3 and MUFA:PUFA ratios. A
previous study reported that a diet composed of 12% caprylic (C8:0) and capric acid
(C10:0), both MCFAs, augments the rate of fat mass loss compared to a diet composed of
12% olive oil that contains mostly MUFAs (91). Furthermore, there is substantial
evidence demonstrating that small doses of MCFAs and HFDs rich in MCFAs can
effectively reduce body weight, fat mass gains, and minimize IR compared to HFDs rich
in LCFAs (92-96). Additionally, MCFA-rich diets have been associated with an
improved cholesterol profile (97-100) and reduced inflammation (101, 102) compared to
other iso-caloric diets. The reported reduction in body weight produced by MCFAs is
associated with higher energy expenditure and up-regulated FA oxidation (103-105). As
a result of their shorter chain length, MCFAs can be transported from the intestines
directly to the liver where they can be quickly oxidized (92, 106). LCFAs, on the other
hand, are first incorporated into chylomicrons before they leave the intestine via the
lymphatic system and travel through the blood to extra-hepatic tissues to be stored or
metabolized. Not only do MCFAs and LCFAs differ in their digestive routes, but their
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propensity to be oxidized is also dissimilar (41). Once inside a cell, MCFAs are less
likely to be stored as AT as they can enter the mitochondria to be oxidized independent of
carnitine palmitoyltransferase 1, unlike LCFAs.
It is important to point out that the MCFA argument may not be valid when
comparing the 6%-SF and 12%-SF diets (.1% versus 3.6% of total calories from MCFAs,
respectively). It is likely that the MCFA-caloric content of the diet would need to be
higher to produce similar effects as generated by the 24%-SF diet. The differences in
adiposity we did observe between the 6%-SF and 12%-SF-fed mice may be due to the
fact that the 12%-SF diet was composed of more obesogenic LCSFAs (8.4% vs. 5.9% of
total calories). However, we find this unlikely as the 24%-SF diet had the largest
percentage of LCSFAs (12.2% of total calories) and resulted in a similar level of
adiposity as the mice consuming the 6%-SF diet.
Another possible rationale for the differences in IR and inflammation across the
diets may be the disparities in the linoleic content (C18:2), (11.4%, 9.4%, and 5.4% of
total caloric intake for the 6%-SF, 12%-SF, and 24%-SF diets, respectively). Even when
controlling for various ratios within an iso-caloric diet, the manipulation of one
macronutrient, or sub-set of macronutrients, results in an uncontrollable alteration of
another. As such, in the current study, alterations in the percentage of SF across diets
also resulted in changes in the percentage of unsaturated fat. Thus, although the ratio of
omega-6:omega-3 FAs was the same for each of the HFDs, the absolute quantity of
linoleic acid in the 6%-SF and 12%-SF diets was greater than in the 24%-SF diet.
Linoleic acid serves as a short-chain, parent omega-6 FA necessary for the synthesis of
essential omega-6 LCFAs (107) that can play an important role in the promotion of
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inflammatory processes through the production of various eicosanoids (43, 107, 108). In
fact, others have shown that a HFD rich in omega-6 FAs can increase inflammation more
so than a HFD rich in SFAs (109). Further, omega-6 FAs are prone to peroxidation
leading to accumulation of 4-Hydroxy-2-nonenal (4-HNE), which has been shown to
induce IR (110).
It is also likely that the differences in MCFAs, LCFAs and linoleic content across
the diets can explain some of the other unexpected reported findings. For instance, the
discrepancies in MCFA and linoleic content between the 6%-SF and 24%-SF diets may
explain the similar adiposity but different levels of IR seen in these groups; previous
work has shown that MCFA-rich diets can hinder the development of IR without
influencing body weight (111). And it may be that the greater content of linoleic acid in
the 6%-SF diet produced significantly more 4-HNE leading to a greater IR compared to
the 24%-SF diet. Also, it is certainly possible that the relatively high content of both
linoleic acid and LCSFAs in 12%-SF diet may explain the high degree of adiposity,
macrophage infiltration and IR compared to the 6%-SF diet. Clearly, the disparate
findings across the three HFDs do not result from variations of a single group of FAs, but
instead stem from alterations in the content of several classes of FAs.
It is well established that SFAs play a role in inflammatory signaling (7, 35, 112,
113). However, the degree to which individual FAs activate pro-inflammatory pathways
remains somewhat controversial as there has been at least one study to report that SFAs
do not activate TLRs in vitro (114). Further, it is evident from our findings as well as
from previous research that varying the composition of dietary SFAs can differentially
regulate inflammatory processes in vivo as compared to in vitro. For example, Lee and
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others have shown that lauric acid (C12:0), a MCFA that varies considerably with
increasing percentage of SF in our diets, can serve as a potent agonist of TLR signaling in
vitro (7, 35). On the contrary, Rivera et. al. (101) reported that a MCFA-rich diet more
effectively attenuated non-alcoholic steatohepatitis and reduced hepatic TLR-4
expression versus a PUFA-rich diet. These convergent findings may be explained by the
inclination of lauric acid to be oxidized in vivo, thus limiting its ability to serve as a
ligand for TLRs (41). This highlights the importance of additional research to better
understand the role of various SFAs on inflammatory-related signaling, and further,
whether the effects observed in vitro are actually reflected in vivo.
Additionally, our data, and that of others, suggests that iso-caloric diets with a
greater content of omega-6 PUFAs can produce greater IR, result in a poorer TC/HDL-C
ratio, and may even increase inflammation (101, 109) more so than an iso-caloric diet
composed of significantly more SF. Meanwhile, others have shown that high
consumption of omega-6 FAs has been associated with reduced inflammation, a more
favorable TC/HDL-C ratio (109) and no negative effects on inflammatory markers (115,
116). It should be noted, however, that the majority of these studies were performed in
humans, where it is extremely difficult to control for the nutrient composition of the diet
and the activity level of the subjects – two factors known to greatly influence metabolism
and inflammation (117, 118). This affirms the need for future research utilizing various
controlled diets to better understand the role that omega-6 FAs have on physiological
processes.
In summary, we examined the influence of three 40% HFDs differing in the
percentage of total calories from SF (6%, 12% and 24%) on body composition,
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macrophage behavior, inflammation, and metabolic dysfunction in mice. In general, the
12%-SF diet, most closely mimicking the standard American diet, led to the greatest
adiposity, macrophage infiltration, and IR, whereas the 24%-SF diet had the lowest levels
of these outcomes. In conclusion, our findings support previously published data that ad
libitum, high-fat feeding can lead to an increased risk of obesity and obesity-related side
effects. However, the extent of excess fat accumulation and adverse health perturbations
is not necessarily proportional to the percentage of SF in the diet. Although SFAs and
omega-6 FAs have been implicated as pro-inflammatory molecules, future research
should examine the degree to which diets differing in SFA and omega-6 FA content
impact individual TLR activation, macrophage behavior, inflammatory signaling and
subsequent metabolic dysfunction as well as the effect that manipulating the absolute
quantities of omega-6 and omega-3 FAs, without changing the ratio between these FAs,
has on these outcomes.
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FIGURES
Table 2.1 Diet composition of treatment diets. SFAs, Saturated Fatty-Acids; MCSFAs,
Medium-Chain Saturated Fatty Acids; LCSFAs, Long-Chain Saturated Fatty Acids;
USFAs, Unsaturated Fatty Acids; MUFAs, Monounsaturated Fatty Acids; PUFAs,
Polyunsaturated Fatty Acids.
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Figure 2.1 The effect of consuming HFDs differing in saturated fat composition on
(A) weekly mean body weight, (B) retroperitoneal (Rp), mesentery (Mes),
epididymal (Epi), and total visceral (Total) fat pad weights, and (C) adipocyte size
at sacrifice (n=8-9). Diets not sharing a common letter differ significantly from one
another (P≤.05). *Significantly different from AIN-76A (week 11: 12%-SF only,
weeks 12-20: 6%-SF, 12%-SF, and 24%-SF diets, P≤.05). &Significantly different
from AIN-76A-Mod (weeks 11-12: 12%-SF only, weeks 13-20: 6%-SF, 12%-SF,
and 24%-SF diets, P≤.05). %Significantly different from 6%-SF (weeks 15, 17-20:
12%-SF only, P≤.05). $Significantly different from 24%-SF (weeks 17-20: 12%-SF
only, P≤.05).

52

Table 2.2 Body composition including, fat mass, lean mass, and body fat % of mice
assessed at baseline (4 weeks) and incrementally (weeks 8, 12, 16 and 20) throughout the
course of the study (n=8-9). Values not sharing a common letter (abcd) differ significantly
over time within the given diet treatment (P≤.05). Values not sharing a common symbol
(&#^%)
differ significantly among diet treatments within the given week (P≤.05).
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Figure 2.2 Epididymal adipose tissue gene expression of (A) F4/80, (B) CD11c, (C)
CD206, and (D) TLR-2 after 16 weeks of diet treatment (n=8-9). Diets not sharing a
common letter differ significantly from one another (P≤.05) (n=8-9). Representative
images of (E) H&E and (F) F4/80 staining of epididymal adipose tissue at a
magnification of 20x for each of the treatment diets.
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Figure 2.3 Representative western blots of (A) phosphorylated p38 MAPK
(Tyr182)/total p38 MAPK, (B) phosphorylated JNK (Thr183/Tyr185)/total JNK, and (C)
phosphorylated p65 NFκB (Ser536)/total p65 NFκB presented relative to control diets in
epididymal adipose tissue following 16 weeks of diet treatment (n=5-6) . Diets not
sharing a common letter differ significantly from one another (P≤.05).
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Figure 2.4 Epididymal adipose tissue gene expression of (A) MCP-1, (B) TNF-α, (C)
IL-6, (D) IL-10, (E) SOCS1, and (F) IFN-γ after 16 weeks of diet treatment (n=8-9).
Diets not sharing a common letter differ significantly from one another (P≤.05).
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Table 2.3 Fasting metabolic panel assessed incrementally (weeks 8, 12, 16 and 20)
throughout the course of the study (n=8-9). Values not sharing a common letter (abc)
differ significantly over time within the group (P≤.05). Values not sharing a common
symbol (&#^%) differ significantly among groups within the given week (P≤.05).
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Chapter III

Impact of Dietary Saturated Fat on Non-Alcoholic Fatty-Liver Disease2

2
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ABSTRACT
We examined the effects of three high-fat diets differing in the percentage of total
calories from saturated fat (SF) (6%, 12%, and 24%), but identical in total fat (40%), on
the progression of Non-Alcoholic Fatty-Liver Disease. Diets were administered for 16
weeks. Hepatic lipid accumulation was assessed gravimetrically and by Oil Red O
staining. Hepatic expression of marker genes for inflammatory mediators (F4/80, TLR-2,
TLR-4, MCP-1, TNF-α, IL-6) was measured along with activation of NFκB, JNK and
p38-MAPK. It was found that a diet’s SF content, independent of total fat, can greatly
impact NAFLD progression. The 6%-SF and 12%-SF diets led to the greatest accretion
of hepatic lipids, whereas the 24%-SF diet resulted in similar hepatic lipid accumulation
as control diets. With regard to inflammation, in general, the 12%-SF diet led to the
greatest degree of inflammation as evidenced by an increase in JNK activation and F4/80
and TLR-4 gene expression.

Keywords: Saturated Fat, High-Fat Diet, Non-Alcoholic Fatty-Liver Disease,
Inflammation, Obesity
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INTRODUCTION

Non-Alcoholic Fatty-Liver Disease (NAFLD) is characterized by evidence of
hepatic steatosis with “no causes of secondary hepatic fat accumulation such as
significant alcohol consumption, use of steatogenic medication, or hereditary
disorders”(1). The disease presents itself in 70-80% of diabetic and obese patients and is
the principal cause of hepatological clinical referrals in the United States (1, 2). NAFLD
is a single term describing two pathological conditions. The first condition, known as
hepatic steatosis, is characterized by the accumulation of excess fat in the liver. Hepatic
steatosis precedes the second condition, non-alcoholic steatohepatitis (NASH), which is
typified not only by hepatic steatosis, but also by hepatic inflammation and hepatocellular
damage.
Hepatic steatosis is a product of a long-term imbalance between caloric intake and
energy expenditure. When caloric intake exceeds energy expenditure, excess energy is
stored in the form of triglycerides in adipocytes. Although adipocytes have a significant
capacity to store energy, a prolonged overindulgence in energy intake without a sufficient
matching energy expenditure can result in adipose tissue dysfunction (3). Adipose tissue
dysfunction is characterized by many factors including, an increase in adipocyte size and
number, adipocyte secretion of pro-inflammatory cytokines, as well as the promotion of a
pro-inflammatory environment and ectopic fat deposition, including the liver (3, 4). As
lipids continue to accumulate in the liver, the liver eventually becomes insulin resistant,
inflamed, and fibrotic (NASH), leading to an increased risk of mortality (1).
Mounting evidence suggests that HFDs promote NAFLD (5, 6). Further, it seems
the type of fat consumed in the diet can greatly affect the development of NAFLD (2);
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both in vitro and in vivo models provide evidence that diets higher in saturated fat induce
endoplasmic reticulum (ER) stress, modulate mitochondrial metabolism, promote an
inflammatory environment, and invoke liver damage (2, 7, 8). However, there have been
no controlled studies, which have examined the effects of HFDs different in the
percentage of saturated fat on NAFLD.
The purpose of this study was to examine the effects of three HFDs differing in
the percentage of total calories from SF (6%, 12%, and 24% of total caloric intake), but
identical in total fat (40%), on the development of NAFLD. We hypothesized that high
dietary fat intake would lead to the development of NAFLD and this effect would be
augmented as the percentage of SF increased.

METHODS
Animals
Male C57BL/6 mice were bred and cared for in the animal facility at the
University of South Carolina. They were housed, four-five per cage, maintained on a
12:12-h light-dark cycle in a low stress environment (22°C, 50% humidity, low noise)
and given food and water ad libitum. Principles of laboratory animal care were followed,
and the Institutional Animal Care and Usage Committee of the University of South
Carolina approved all experiments.

Diets
At four weeks of age, mice were randomly assigned to 1 of 5 treatment diets
(n=8-9/group): two control diets (AIN-76A, AIN-76A Mod) and three HFDs (6%-SF,
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12%-SF, and 24%-SF) (BioServ, Frenchtown, NJ) (Table 1). The percentage of calories
provided by each of the three macronutrients, the ratio of
polyunsaturated:monounsaturated FAs (PUFA:MUFA), and the ratio of omega-6:omega3 FAs were identical for the HFDs and were designed to be similar to the standard
American diet (9, 10). The second control diet (AIN-76A Mod) was used in order to
match the PUFA:MUFA and omega-6:omega-3 ratios of the HFDs.

Tissue collection
At 20 weeks of age, mice were sacrificed for tissue collection. The liver was
removed and immediately snap-frozen in liquid nitrogen and stored at -80°C.

Oil Red O Staining and Tissue Lipid Accumulation
Frozen 10 µm liver sections were cut using a cryostat (Leica Biosystems,
Germany) set at -20ºC. Hematoxylin and eosin (H&E) and oil red o (Sigma, St. Louis,
MO) staining of the liver was performed as previously described (11). Lipids were
isolated from the liver utilizing the Folch extraction method and were quantified
gravimetrically (12).

Western Blots
The liver was homogenized in radioimmunoprecipitation buffer (Sigma, St. Louis,
MO), which included a protease inhibitor cocktail (Sigma, St. Louis, MO), and 1%
glycerophosphate (100x), 0.5% sodium orthovanadate (1 mM), and 1% sodium fluoride
(5 mM). The protein concentration was determined by the Bradford method. Western
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blots were performed as previously described using primary antibodies for
phosphorylated (Ser536) and total NFkB p65, phosphorylated (Thr183/Tyr185) and total
JNK (Cell Signaling, Danvers, MA), and phosphorylated (Tyr182) and total p-38 MAPK
(Santa Cruz Biotechnology Inc., Santa Cruz, CA) (13). As there were no differences in
the activation of any of the measured proteins between the two control diets (AIN-76A
and AIN-76A Mod), these samples were combined to represent the “control” diets for
these analyses.

Gene expression
The liver was homogenized under liquid nitrogen using a polytron and total RNA
was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). Quantification of hepatic
gene expression for F4/80, MCP-1 (monocyte chemotactic protein-1), IL-6 (interleukin
6), TLR-4, TLR-2, and TNF-α (tumor necrosis factor-alpha) was performed as previously
described (14) using Applied Biosystems reagents (Foster City, CA).

Statistical analysis
All data were analyzed using a one-way ANOVA using commercial software
(SigmaStat, SPSS, Chicago, IL). Student-Newman-Keuls test was used for all post-hoc
analyses. Statistical significance was set with an alpha value of P≤0.05. Data are
presented as mean (±SEM).

RESULTS
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Excess lipid accumulation is evident in hepatic tissue of 6%-SF and 12%-SF-fed
mice

Although the mechanisms at the root of ectopic fat storage are not completely
understood it is believed that in a chronic positive energy state, the capacity for
subcutaneous adipose tissue to store triglycerides reaches a limit after which excess
energy is allocated to ectopic fat depots and stored as triglycerides. Accrual of ectopic fat
has been linked to an array of molecular dysfunctions (3, 15, 16).
We show a significant accumulation of excess lipids in the liver as a result of
HFD-consumption. Interestingly, only the 6%-SF and 12%-SF diets produced this effect;
the 24%-SF diet resulted in a similar level of hepatic lipid accumulation as the control
diets (P<.05) (Figure 3.1A-B).

Upregulation of JNK activation in the liver of the 12%-SF diet
Inflammation has been closely linked with metabolic dysfunction, including
insulin resistance (17). Hepatic phosphorylated-JNK (p-JNK) was the only inflammatory
signaling molecule found to be upregulated in the liver; it was found to be significantly
elevated in the 12%-SF diet compared to the control and 6%-SF-fed mice (P≤.05) (Figure
3.2).

Inflammation minimal to non-existent in the hepatic tissue of HFD-fed mice
With regard to inflammatory markers, the 12%-SF diet increased hepatic F4/80
and TLR-4 expression compared to both control diets and the AIN-76A diet, respectively
(P≤.05) (Figure 3.3). Regarding the 6%-SF and 24%-SF diets, only the 24%-SF diet
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elicited any increase in any of the inflammatory markers measured as the 24%-SF-fed
mice displayed an increase in hepatic TNF-α expression compared to the AIN-76A-fed
mice (P≤.05) (Figure 3.3).

DISCUSSION

Obesity is characterized by the accumulation of excess body fat and an increased
risk of disease resulting from a complex network of interrelated molecular perturbations,
including ectopic lipid accumulation in the liver leading to the development of NAFLD.
Large lipid depositions in the liver (hepatic steatosis) have been shown to play a
prominent role in the development of metabolic dysfunction (16, 18). However, the
degree to which NAFLD is influenced by lipid composition has not been completely
resolved. We have recently reported that adiposity, macrophage behavior, inflammation,
and insulin resistance can be greatly affected by dietary SF content (19). However, it was
found that these outcomes are not necessarily proportional to the percentage of SF in the
diet; a diet most closely mimicking the standard American diet (12% and 40% of overall
calories from saturated fat and total fat, respectively) led to the greatest adiposity,
macrophage infiltration into adipose tissue, and insulin resistance, whereas diets
composed of 6% (6%-SF) and 24% (24%-SF) of total calories from SF, but an equivalent
level of overall calories from fat (40%), produced lower levels of these variables with the
24%-SF diet resulting in the least degree of insulin resistance. We felt that these results
warranted a more thorough examination into the influence that HFDs, of varying SF
content, have on NAFLD. It was discovered that a diet’s SF content, independent of total
fat, can greatly impact NAFLD progression.
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We found that consumption of the 6%-SF and 12%-SF diets resulted in elevated
levels of lipid accumulation compared to the control or 24%-SF diets. We next examined
inflammatory signaling molecules as well as markers of inflammation. We have
previously reported that adipose tissue concentration of phosphorylated JNK was
significantly increased in all HFDs, whereas only the 12%-SF-fed mice exhibited a
significantly higher degree of NFκB p65 activation compared to control-fed mice (19).
Of the three inflammatory pathways examined, only hepatic phosphorylated JNK was
significantly elevated in 12%-SF-fed mice compared to control and 6%-SF-fed mice.
Upon activation, JNK can produce insulin resistance via serine phosphorylation of IRS-1
(20). The 12%-SF mice also exhibited increased expression of the macrophage marker,
F4/80, and TLR-4. It is well known that non-alcoholic fatty liver disease is a progressive
disorder in which hepatic steatosis precedes non-alcoholic steatohepatitis. Based upon
the results of this study, it seems that JNK activation, and accumulation of macrophages
precede the full progression into steatohepatitis. Thus, it is likely that a longer period of
HF feeding would be necessary before the development of a substantial hepatic proinflammatory environment. The finding that the consumption of the 24%-SF diet
resulted in elevated hepatic TNF-α gene expression without any significant change in
phosphorylated JNK, p38 MAPK, NFκB-p65 indicates that other signaling pathways are
likely involved in influencing the expression of this inflammatory marker.
It is evident that the hepatic tissue of the 12%-SF-fed mice exhibited more
characteristics of deregulatory processes than the hepatic tissue of the 6%-SF-fed mice
despite having similar levels of hepatic lipid accumulation. The difference in cellular
disturbances may be due to the concentration of SFAs in the 6%-SF and 12%-SF diets

66

and/or the FA composition of the hepatic lipid depositions. SFAs are precursors for
intracellular lipid intermediates, such as diacylglycerols and ceramides, which can
function as secondary messengers within the cell and have been linked to metabolic
dysfunction (16). In support of this, Wang et. al., through the utilization of two HFDs,
one composed largely of SFAs and the other composed primarily of PUFAs, showed that,
despite a similar degree of hepatic steatosis, the SFA-ladened diet resulted in a greater
concentration of hepatic SFA accumulation producing ER stress and apoptosis – two
perturbations not induced by the PUFA-rich diet (7). The result that the 24%-SF diet did
not produce hepatic steatosis is likely due to the increased MCFA content of the diet
(12% versus .1% and 4% of total caloric intake for the 24%-SF, 6%-SF, and 12%-SF
diets, respectively). As a result of their shorter chain length, MCFAs are more likely to
be oxidized (21, 22). For a more elaborate explanation on why differences in SF
composition existed among the HFDs and a more thorough background on MCFAs
influencing metabolic processes, please see Enos et. al. (19).
In conclusion, this is the first study to examine the influence of three HFDs
differing in the percentage of total calories from saturated fat (6%, 12%, 24%), but
identical in total fat (40%), on NAFLD development. Findings from this study paired
with those from our previous study (19) show that the SFA composition of a HFD can
greatly influence the processes responsible for obesity-related diseases, as well as provide
further evidence that the mechanisms at the root of these diseases are diet and tissuesensitive. In the future, time-line and dietary manipulation studies should be employed to
better understand the tissue-specific pathology of dysfunctional cellular processes and the
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influence that dietary manipulation has on these outcomes so that therapeutic modalities
may be conceived to more efficiently combat the obesity epidemic.
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Figure 3.1. Hepatic lipid accumulation. Relative (A) hepatic lipid accumulation (n=59/group) representative images of H&E and (B) oil red o staining of liver shot at a
magnification of 10x.
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Figure 3.2. Inflammatory signaling. Representative western blots of p-JNK, p-p38
MAPK, and p-NFκB p65 in liver. Diets not sharing a common letter differ significantly
from one another (P≤.05). Western blots presented as relative intensity of densitometry
(IOD).
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TLR-4, and TLR-2 in liver (n=8-9/group). Diets not sharing a common letter differ
significantly from one another (P≤.05).
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Chapter IV

A High-Fat Diet Supplemented with Quercetin Has No Effect at Attenuating Adipose
Tissue Inflammation or Hepatic Steatosis3

3

Enos, R. T., J. M. Davis, K. T. Velazquez, J. L. McClellan, and E. A. Murphy. To be
submitted to a journal TBD.
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ABSTRACT
We investigated the effects of a high-fat diet (HFD) supplemented with quercetin
(.02%) on body composition, adipose and hepatic tissue inflammatory signaling and
inflammation, and glucose metabolism in mice. Diets were administered for 16 weeks.
Body composition and fasting blood glucose were examined intermittingly. Hepatic lipid
accumulation as well as adipose tissue (AT) and liver expression of inflammatory
mediators (F4/80, CD206 (AT only), TLR-2 (AT only), TLR-4 (AT only), MCP-1, TNFα, IL-6 (AT only), IL-10 (At only)) were measured along with activation of NFκB, and
JNK. Contrary to the findings of others, quercetin supplementation had no effect at
mitigating adipose tissue inflammation, hepatic steatosis, or improving body composition
or fasting blood glucose levels.
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INTRODUCTION
Obesity has quickly become a major health concern not only in the United States,
but throughout the world.

Moreover, it seems that the rate of obesity is on the rise. In

1980, as little as thirty years ago, the rate of obesity in the adult population was half
(15%) of what it is now (30%). Even more worrisome, is that WHO projects that by
2015 there will be approximately 2.3 billion and 700 million overweight and obese
individuals, respectively.
The health risks associated with obesity not only affect the individual suffering
from obesity, but they also negatively impact the economy. It is estimated that obesity
costs the economy of the United States more than 120 billion dollars annually (1). The
120 billion dollar stress on the economy is due many factors, including but not limited to:
an increase in health care services that are needed as a direct result of the escalating rate
of obesity and decreased productivity resulting from missed work time and premature
death. Additionally, taxpayers are burdened with high health care costs, which impacts
the price of goods and employee raises (2).
Obesity is problematic as the condition is characterized by a chronic state of lowgrade adipocyte inflammation linked to adipose tissue dysfunction. Whether the adipose
tissue dysfunction precedes the low-grade inflammatory state, or vice versa, is debatable.
Nonetheless, adipose tissue dysfunction and the associated low-grade inflammation have
been shown to increase the rate of mortality and are characterized by a circular cascade
of interconnected events including, but not limited to, an increase in adipocyte size and
number, endoplasmic reticulum stress, adipose tissue hypoxia, increased infiltration of
pro-inflammatory macrophages into adipose tissue, an increase in adipocyte, preadipocyte, and macrophage TLR-4 and TLR-2 protein content, an increase in circulating
75

pro-inflammatory cytokines, insulin resistance, and a decrease in mitochondrial function
(3-9).
Due to the fact that western countries are plagued by diseases resulting from
obesity, it has become the goal of scientists to come up with relatively inexpensive
therapeutic interventions to help mitigate HFD-enhanced chronic inflammation in order
to improve quality of life and decrease obesity-related deaths. Recently, scientists have
utilized nutraceutical interventions to examine the effects that plant-derived metabolites
have on obesity outcomes. There exists promising research that the naturally occurring
flavonoid, quercetin, possesses anti-inflammatory properties and an anti-obesogenic
effect when supplemented along with a HFD (10-16). However, the mechanism(s) by
which quercetin elicits its positive effects and the influence that quercetin has on
macrophage behavior is still poorly understood.
The purpose of this study was to examine the potential anti-inflammatory and
anti-obesogenic benefits of .02% quercetin supplementation to a HFD. We hypothesized
that quercetin supplementation would decrease adiposity, adipose and hepatic tissue
inflammation, and would improve fasting blood glucose compared to consumption of a
HFD alone.

METHODS
Animals
Male C57BL/6 mice were bred and cared for in the animal facility at the
University of South Carolina. They were housed, four-five per cage, maintained on a
12:12-h light-dark cycle in a low stress environment (22°C, 50% humidity, low noise)
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and given food and water ad libitum. Principles of laboratory animal care were followed,
and the Institutional Animal Care and Usage Committee of the University of South
Carolina approved all experiments.

Diets
At four weeks of age, mice were randomly assigned to 1 of 3 treatment diets
(n=10/group): a control diet (AIN-76A), a HFD, and the HFD supplemented with .02%
quercetin (HFD + Quer) (BioServ, Frenchtown, NJ). The percentage of calories provided
by each of the three macronutrients, the ratio of polyunsaturated:monounsaturated FAs
(PUFA:MUFA), and the ratio of omega-6:omega-3 FAs were identical for the HFDs and
were designed to be similar to the standard American diet (17, 18).

Body weights, food intake, and body composition
Body weight and food intake were monitored weekly. Body composition was
assessed every four weeks (weeks 4, 8, 12, 16, and 20). For this procedure, mice were
placed under brief anesthesia (isoflurane inhalation) and were assessed for lean mass, fat
mass, and body fat percentage via dual-energy x-ray absorptiometry (DEXA) (Lunar
PIXImus, Madison, WI).

Fasting blood glucose
Plasma was assessed for fasting concentrations of glucose at 16 and 20 weeks of
age. Blood samples were collected from the tip of the tail after a five-hour fast. Blood
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glucose concentrations were determined in whole blood using a glucometer (Bayer
Contour, Michawaka, IN).

Tissue collection
At 20 weeks of age, mice were sacrificed for tissue collection. Epididymal,
mesentery, and retroperitoneal fat pads, as well as the liver, were removed, weighed, and
immediately snap-frozen in liquid nitrogen and stored at -80°C or fixed in 10% formalin
until analysis. Blood was collected from the inferior vena cava using heparinized
syringes, and centrifuged at 4,000 rpm for 10 min at 4°C. Plasma was aliquoted and
stored at −80°C.

Hepatic lipid accumulation
At sacrifice, the liver was excised from each mouse and immediately snap-frozen
in liquid nitrogen and stored at -80°C. Lipids were isolated from the liver utilizing a
modified Folch extraction method and were quantified gravimetrically (19).

Western blots
Epididymal AT and liver were homogenized in radioimmunoprecipitation buffer
(Sigma, St. Louis, MO), which included a protease inhibitor cocktail (Sigma, St. Louis,
MO), and 1% glycerophosphate (100x), 0.5% sodium orthovanadate (1 mM), and 1%
sodium fluoride (5 mM). The protein concentration was determined by the Bradford
method (20). Western blots were performed as previously described using primary
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antibodies for phosphorylated (Ser536) and total NFkB p65 and phorphorylated
(Thr183/Tyr185) and total JNK (Cell Signaling, Danvers, MA) (21).

Gene expression
Epididymal AT and liver were homogenized under liquid nitrogen using a
polytron and total RNA will be extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA) and RNeasy mini-spin columns (adipose tissue only) (Qiagen, Valencia, CA).
Quantification of epididymal AT gene expression for F4/80, CD11c, CD206, MCP-1, IL6, TLR-4, TLR-2, and TNF-α and liver gene expression of F4/80, TNF-α, and MCP-1
(Applied Biosystems, Foster City, CA) were performed as previously described (22).

Statistical analysis
All data were analyzed using commercial software (SigmaStat, SPSS, Chicago,
IL). Body weight, body composition outcomes, and fasting blood glucose were analyzed
using a repeated measures two-way ANOVA. All other data were analyzed using a oneway ANOVA. Student-Newman-Keuls test was used for all post-hoc analyses.
Statistical significance was set with an alpha value of P≤0.05. Data are presented as mean
(±SEM).

RESULTS
HFD and HFD + Quer produce a similar increase in body weight, but quercetin
supplementation increases overall and visceral fat mass more so than HFD alone
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Body weights and fat pad weights are presented in Figure 4.1. The mice
consuming the HFD and HFD + Quer diet had significantly elevated body weights
compared to AIN-76A-fed mice starting at 11 weeks of age (P<.05).
For the fat-pad depots, both the HFD mice and the HFD + Quer mice had
significantly more fat mass stored in the mesentary and epididymal fat pads compared to
AIN-76A mice (P<.05). However, only consumption of the HFD + Quer increased the
retroperitoneal fat pad weight in comparison to the AIN-76A mice (P<.05).
Furthermore, although both HFDs increased total visceral adipose tissue compared to the
AIN-76A diet, the HFD + Quer led to a greater accumulation of visceral adipose tissue
than the HFD-fed mice (P<.05).
Body composition analysis revealed a significant difference among groups
(P<.05) (Table 4.1). Specifically, the HFD-fed mice, with or without quercetin
supplementation, had a greater fat mass compared to AIN-76A-fed mice starting at 12
weeks (P<.05). However, the HFD + Quer led to a significant increase in fat mass at 16
weeks (P<.05) and a trend (P<.1) for a greater fat mass at 20 weeks compared to the HFD
alone. Regarding body fat percentage, the HFD + Quer diet elicited a significant increase
in body fat percentage compared to AIN-76A-fed mice starting at 8 weeks and in
comparison to HFD-fed mice at week 8 only (P<.05). On the other hand, the HFD-fed
mice did not increase body fat percentage relative to the AIN-76A-fed mice until 12
weeks (P<.05). In general, lean mass increased over time for all groups, and by week 16,
the HFD and HFD + Quer mice exhibited greater lean mass compared to AIN-76A fed
mice (P<.05).
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It was not possible to calculate individual food intake as mice were housed 45/cage. However, in general, we did not observe any differences, among the HFD-fed
mice, in weekly food intake (food consumed by mice in each cage/number of mice in
cage) over the course of the study.

Quercetin supplementation does not attenuate adipose tissue inflammation despite
no significant increasing in adipose tissue NFκB activation
Both HFDs increased adipose tissue JNK activation (P<.05) (Figure 4.2B ),
however, only the HFD-fed mice without quercetin supplementation significantly
increased adipose tissue NFκB activation compared to AIN-76A-fed mice (P<.05).
Similar to JNK activation, both HFDs increased gene expression of all inflammatory
markers in the adipose tissue in comparison to AIN-76A-fed mice (P<.05) (Figure 4.3);
the only exception being TLR2, which was found to be significantly different among the
three diets, with the HFD + Quer eliciting the greatest increase in TLR2 expression
followed by the HFD and AIN-76A diet, respectively (P<.05).

HFDs increase liver weight as a percentage of body weight as well as hepatic lipid
accumulation
Both the HFD and the HFD + Quer led to an increase in liver weight relative to
body weight as well as an increase in hepatic lipid accretion (Figure 4.4A,B) (P<.05).

Hepatic inflammation is augmented in HFD and HFD + Quer mice
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Consumption of a HFD regardless of quercetin supplementation increased JNK
activation and MCP-1 gene expression, but did not significantly increase NFκB activation
or TNF-α expression (Figures 4.5A,B and 4.6) (P<.05). Interestingly, the addition of
quercetin increased F4/80 gene expression above both the AIN-76A-fed mice and the
HFD-fed mice (Figure 4.6) (P<.05).

Both HFDs increase fasting blood glucose
Compared to the AIN-76A-fed mice, both the HFD and HFD + Quer-fed mice
exhibited an increase in fasting blood glucose levels at 16 and 20 weeks (Table 4.2).

DISCUSSION

Obesity has become a global health concern as obese individuals are at a greater
risk for developing life-threatening diseases. For example, obesity, linked to the
consumption of a high-fat, Western diet, has been established as significant risk factors
for cancer development and cancer-related mortality (9, 23, 24). With the rising cost of
health insurance and healthcare costs it is imperative that relatively inexpensive, effective
therapeutic interventions are utilized in order to improve quality of life, decrease obesityrelated diseases, as well as minimize the economic burden created by obesity. Therefore,
we examined if a HFD supplemented with the anti-inflammatory phytochemical,
quercetin, could help mitigate the physiological perturbations linked to HFD-induced
obesity. Contrary to the findings of others, quercetin supplementation had no effect at
mitigating adipose tissue inflammation, hepatic steatosis, or improving body composition
or fasting blood glucose levels.
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Previously, a study performed by Jung et. al. found that, in mice, a 32% HFD
supplemented with .025% quercetin for 9 weeks reduced body weight, liver weight, and
white adipose tissue weight compared to mice consuming a HFD without quercetin (15).
Along a similar note, in mice, Koboriet. et. al. also found that a HFD supplemented with
.05% quercetin for 20 weeks hindered the development of hepatic steatosis and reduced
visceral adipose tissue accumulation (11). In our study, however, quercetin did not
exhibit any anti-obesogenic properties; in fact, in some analyses quercetin was actually
found to be obesogenic. Although, in general, we did not see any significant changes in
body weight between the HFD and the HFD + Quer, quercetin supplementation did result
in an increase in visceral fat mass compared to the HFD alone. Furthermore, there was
no difference between the HFD-fed mice and the HFD + Quer mice with regard to
hepatic lipid accumulation.
Because quercetin is known to possess anti-inflammatory properties, which are
believed to be modulated by quercetin's ability to modulate NFκB expression (16), we
examined NFκB activation in the adipose tissue along with JNK activation, another proinflammatory signaling protein, which we have previously shown to be upregulated in the
adipose tissue of mice consuming the HFD utilized in this study (25). It was found that
quercetin supplementation hampered an increase in NFκB activation, but did not have
any effect on mitigating JNK activation. Interestingly, however, consumption of both the
HFD and the HFD + Quer resulted in similar degrees of adipose tissue inflammation as
determined by RT-PCR despite no significant increase in NFκB activation in the HFD +
Quer group. These results suggest that: (1) quercetin may be directly or indirectly
modulating NFκB activation and (2) the NFκB signaling cascade may not be the primary
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pro-inflammatory pathway that is involved in adipose tissue inflammation given that
there was no change in adipose tissue inflammatory mediators between the HFD and
HFD + Quer groups.
The liver was subsequently investigated in order to assess hepatic inflammation.
Similar to the adipose tissue, we examined NFκB and JNK activation as well as F4/80,
MCP-1, and TNF-α gene expression. We found no increase in NFκB activation, but
activation of JNK was increased in both the HFD and HFD + Quer groups as well as
MCP-1 mRNA expression. An interesting observation was the fact that quercetin
supplementation increased F4/80 gene expression in the liver more so than either the
AIN-76A or HFD-fed mice. However, a more thorough analysis is needed to determine
the reason for the significant increase in hepatic F4/80 expression resulting from
quercetin supplementation.
In order to assess how quercetin supplementation influenced glucose metabolism,
fasting blood glucose was analyzed at 16 and 20 weeks. Glucose levels were found to be
elevated for both HFDs at 16 and 20 weeks, however, there was no difference in glucose
levels among HFD treatments. This supports, although not definitively, as fasting insulin
concentrations were not evaluated, the finding of Stewart et. al. who showed that
quercetin supplementation may not improve insulin sensitivity (26).
In summary, quercetin supplemented to a HFD at .02% for a period of 16 weeks
did not provide any anti-inflammatory or anti-obesogenic effects in mice. In fact,
quercetin supplementation was found to be obesogenic and elicited an increase in hepatic
F4/80 gene expression. These findings are in great contrast to the findings of others. The
discrepencies in findings between studies is likely due to the length of HFD
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administration, the concentration of quercetin used, as well as the type of HFD utilized.
This study is limited by the fact that lipid metabolism and various other pro-inflammatory
markers were not measured, as it is possible that quercetin may be influencing other
processes not directly analyzed in this investigation. However, it is evident that future
studies are needed to better understand how the interaction between high-fat feeding and
quercetin supplementation influences physiological processes.
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Figure 4.1 The effect of consuming a HFD with, or without, .02% quercetin
supplementation on (A) weekly mean body weight and (B) retroperitoneal (Rp),
mesentery (Mes), epididymal (Epi), and total visceral (Total) fat pad weights at sacrifice
(n=10). Diets not sharing a common letter differ significantly from one another (P≤.05).
*
Significantly different from AIN-76A (week 10-20: HFD & HFD + Quer, P≤.05).
$
Significantly different from HFD & AIN-76A (week 10: HFD + Quer, P≤.05).
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Table 4.1 Body composition including, fat mass, lean mass, and body fat % of mice
assessed at baseline (4 weeks) and incrementally (weeks 8, 12, 16 and 20) throughout the
course of the study (n=10). Values not sharing a common letter (abcde) differ significantly
over time within the given diet treatment (P≤.05). Values not sharing a common symbol
(&#^)
differ significantly among diet treatments within the given week (P≤.05).
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Figure 4.2 Representative western blots of (A) phosphorylated p65 NFκB (Ser536) and
(B) phosphorylated JNK (Thr183/Tyr185)/total JNK, presented relative to control diets in
epididymal adipose tissue following 16 weeks of diet treatment (n=8). Diets not sharing
a common letter differ significantly from one another (P≤.05).
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Figure 4.3 Epididymal adipose tissue gene expression of F4/80, CD11c, CD206, MCP1, TNF-α, IL-10, TLR2, and TLR4 after 16 weeks of diet treatment (n=10). Diets not
sharing a common letter differ significantly from one another (P≤.05).
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from one another (P≤.05).
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Figure 4.5 Representative western blots of (A) phosphorylated p65 NFκB (Ser536)/total
NFκB and (B) phosphorylated JNK (Thr183/Tyr185)/total JNK, presented relative to
control diets in liver following 16 weeks of diet treatment (n=8). Diets not sharing a
common letter differ significantly from one another (P≤.05).
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Figure 4.6 Hepatic gene expression of F4/80, MCP-1, and TNF-α after 16 weeks of diet
treatment (n=10). Diets not sharing a common letter differ significantly from one another
(P≤.05).
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Table 4.2 Fasting blood glucose (mg/dL) collected at 16 and 20 weeks (n=10). Values
not sharing a common symbol (&#) differ significantly among diet treatments within the
given week (P≤.05).
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Overall Conclusion
Overall, results from these studies suggest that adiposity, macrophage behavior,
inflammation, insulin resistance, and NAFLD progression can be greatly affected by
dietary SF content. However, it was found that these outcomes are not necessarily
proportional to the percentage of SF in the diet; a diet most closely mimicking the
standard American diet (12% and 40% of overall calories from saturated fat and total fat,
respectively) led to the greatest adiposity, macrophage infiltration into adipose tissue, and
insulin resistance, whereas diets composed of 6% (6%-SF) and 24% (24%-SF) of total
calories from SF, but an equivalent level of overall calories from fat (40%), produced
lower levels of these variables with the 24%-SF diet resulting in the least degree of
insulin resistance and hepatic lipid accumulation. Further, contrary to the findings of
others, the anti-inflammatory flavonoid, quercetin, had no effect at mitigating adipose
tissue inflammation, hepatic steatosis, or improving body composition or fasting blood
glucose levels in a HFD-induced obesity model. Future studies are needed to better
understand how the interaction between high-fat feeding and quercetin supplementation
influences physiological processes.
.
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